Improving chemotherapy and immunotherapy for pancreatic cancer using light activation
Official title: Molecular Imaging Guidance for Potentiating Chemoimmunotherapy in Pancreatic Cancer using Photodynamic Priming
Funded at University of Texas Dallas · NIH-11122217 · Data updated 2026-11-12
This study is exploring a new way to make chemotherapy and immunotherapy work better for people with pancreatic cancer by using light to activate a special treatment that helps the drugs reach the tumor more effectively and boosts the immune response, all while using advanced 3D models to improve the approach.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Dallas NIH-funded |
| Lab location | 1 site (Richardson, United States) |
| Project start | July 1, 2024 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $488,912 |
| NIH project number | 5R01EB034360-02 |
| Project ID | NIH-11122217 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with locally advanced or metastatic disease.
✕Less likely to help
Patients with resectable pancreatic cancer or those who have already undergone extensive treatment may not benefit from this research.
What this research studies
This research investigates a novel approach to enhance the effectiveness of chemotherapy and immunotherapy in patients with pancreatic cancer. It utilizes a technique called photodynamic priming, which involves using light to activate a non-toxic treatment that helps improve drug delivery and counteracts the tumor's immunosuppressive environment. By addressing the challenges posed by desmoplasia, this method aims to increase the response rates to existing treatments, potentially leading to better patient outcomes. The research will involve advanced 3D modeling to understand the tumor environment and optimize treatment strategies.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment responses for patients with pancreatic cancer.
How similar studies have gone: While the approach of using photodynamic therapy is established, its application in enhancing chemo-immunotherapy for pancreatic cancer is novel and has not been extensively tested.
Where this research is happening
-
University of Texas Dallas
Richardson, United States Active
Researchers
- Principal investigator: Obaid, Girgis — University of Texas Dallas
- Study coordinator: Obaid, Girgis
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.